we conclude that verapamil , at concentrations clinically achieved in the myocardium ( approximately 1 microm ) , competitively inhibits binding to alpha 1-adrenergic and muscarinic receptors and that this inhibition may play a role in the effects of verapamil on the heart .
C0027061
myocardium
C0018787
heart